The complaint alleges that Insulet maintained defective manufacturing controls, heightening the risk of safety violations. According to the filing, the company’s public statements during the class period were materially misleading, particularly concerning the scope of a March 2026 medical device correction. The lawsuit contends that the manufacturing issues impacted a significantly larger volume of Pod products than the company originally disclosed to shareholders.

Those seeking to participate in the litigation must contact Brian Schall at the firm’s Los Angeles office before the August 31, 2026, deadline. As the class has not yet been certified, shareholders who choose to remain passive will currently function as absent class members. The Schall Law Firm, which specializes in shareholder rights, is offering consultations for investors to discuss potential recovery for damages sustained when the market adjusted to the disclosed manufacturing failures.